Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Esperion Therapeutics Inc shares valued at $79,240 were purchased by Koenig Sheldon L. on Sep 17 ’25. At $2.79 per share, Koenig Sheldon L. acquired 28,427 shares.
Also, Halladay Benjamin purchased 7,046 shares, netting a total of over 19,789 in proceeds.
Before that, Looker Benjamin had added 6,267 shares to its account. In a trade valued at $17,576, the Officer bought Esperion Therapeutics Inc shares for $2.80 each.
As published in their initiating research note from Goldman on December 18, 2024, Esperion Therapeutics Inc [ESPR] has been a Neutral and the price target has been revised to $4. Analysts at Cantor Fitzgerald started covering the stock with ‘”an Overweight”‘ outlook in a report released in mid December. As of June 20, 2024, BofA Securities has decreased its “Neutral” rating to a “an Underperform” for ESPR. Earlier on January 03, 2024, BofA Securities downgraded its rating. Their new recommendation was “a Neutral” for ESPR stock which previously was a “a Buy”.
Analyzing ESPR Stock Performance
On last trading session, Esperion Therapeutics Inc [NASDAQ: ESPR] plunged -1.81% to $2.72. The stock’s lowest price that day was $2.694, but it reached a high of $2.8494 in the same session. During the last five days, there has been a surge of approximately 4.62%. Over the course of the year, Esperion Therapeutics Inc shares have jumped approximately 42.41%.
Is Esperion Therapeutics Inc subject to short interest?
Stocks of Esperion Therapeutics Inc saw a sharp steep in short interest on 2025-08-29 dropping by -0.78 million shares to 22.35 million. Data from Yahoo Finance shows that the short interest on 2025-07-31 was 23.13 million shares. A decline of -3.49% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 4.33 of the overall float, the days-to-cover ratio (short ratio) decline to 4.33.
Which companies own the most shares of Esperion Therapeutics Inc (ESPR)?
In terms of Esperion Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 12 in the next 12 months, up nearly 333.21% from the previous closing price of $2.77. Analysts anticipate Esperion Therapeutics Inc stock to reach 20 by 2025, with the lowest price target being 8. In spite of this, 8 analysts ranked Esperion Therapeutics Inc stock as Buy at the end of 2025.
